Following her resignation, effective April 6, Agarwal will serve as a senior medical consultant to Epizyme. In that capacity to the company, she will be its acting chief medical and development officer.
The consulting services will be provided for one year and could extend or be modified subject to the mutual consent of both parties.
Price: 1.07, Change: +0.02, Percent Change: +1.9